Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals

Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals

A new Escherichia coli-produced human papillomavirus (HPV)-16/18 vaccine has been shown to be safe and highly efficacious and was recently licensed in China. As a post hoc analysis of the phase III trial, this study aimed to assess the impact of vaccination time deviations on the specific antibody r...

Full description

Bibliographic Details
Main Authors: Xiao-Juan Yu, Juan Li, Zhi-Jie Lin, Hui Zhao, Bi-Zhen Lin, You-Lin Qiao, Yue-Mei Hu, Li-Hui Wei, Rong-Cheng Li, Wei-Dan Huang, Ting Wu, Shou-Jie Huang, Chang-Gui Li, Hui-Rong Pan, Jun Zhang
Format: Article
Language:English
Published: Taylor & Francis Group 2020-07-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
human papillomavirus vaccine
escherichia coli
bivalent
vaccination interval
immunogenicity
antibody response
Online Access:http://dx.doi.org/10.1080/21645515.2020.1761202

Internet

http://dx.doi.org/10.1080/21645515.2020.1761202

Similar Items